

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)



(10) International Publication Number
WO 2020/167844 A1

(51) International Patent Classification:
C07D 471/04 (2006.01)

(21) International Application Number:
PCT/US2020/017764

(22) International Filing Date:
11 February 2020 (11.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
FR1902018 12 February 2019 (12.02.2019) FR

(71) Applicant: **IMPACT BIOMEDICINES, INC.** [US/US];
86 Morris Avenue, Summit, New Jersey 07901 (US).

(72) Inventors: **ROBERT, Benoit**; c/o Impact Biomedicines,
Inc., 86 Morris Avenue, Summit, New Jersey 07901 (US).
BILLOT, Pascal; c/o Impact Biomedicines, Inc., 6 Morris
Avenue, Summit, New Jersey 07901 (US).

(74) Agent: **SHINALL, Michael A.** et al.; Choate, Hall & Ste-
wart LLP, Two International Place, Boston, Massachusetts
02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(54) Title: CRYSTALLINE FORMS OF A JAK2 INHIBITOR

(57) Abstract: The present disclosure provides crystalline forms of a JAK2 inhibitor, compositions thereof and methods of treating a JAK2-mediated disorder.

WO 2020/167844 A1